Introduction
Polymorphonuclear neutrophils (PMNs) are an integral component of the periodontal host response and represent the overwhelming majority (95%) of leukocytes recruited to the gingival crevice in response to the tooth-associated biofilm (Champagne et al. 2003; Delima and Van Dyke 2003; Lakschevitz et al. 2013; Hajishengallis and Hajishengallis 2014; Sima et al. 2014) . PMNs exit the gingival plexus of blood vessels and enter the crevice via the gingival junctional epithelium, which, under inflammatory conditions, is largely occupied by trafficking PMNs (Delima and Van Dyke 2003) . PMNs primarily play a defensive role, but there is adequate evidence to show that a significant portion of the inflammatory destruction of the periodontium occurs as a result of collateral damage caused by "hyperactive" PMNs or PMNs present in excessive numbers (Chapple and Matthews 2007; Ryder 2010; Eskan et al. 2012; Lakschevitz et al. 2013; Eke et al. 2015) .
In contrast to the general idea that PMNs belong to a homogeneous population and end-stage effector cells, recent studies elegantly show a clear functional compartmentalization of these cells (Carmona-Rivera and Kaplan 2013; Cloke et al. 2013; Sagiv et al. 2015) . Also, recent studies have reported characteristic oral PMN phenotypes associated with periodontitis (Johnstone et al. 2007; Aboodi et al. 2011; Lakschevitz et al. 2013; Fine et al. 2016 ). However, oral tissue and circulatory PMN characteristics in gingivitis are yet to be defined. Gingivitis is a reversible inflammatory condition of the gingival tissues and, unlike periodontitis, does not involve attachment loss or alveolar bone loss. Plaque-induced gingivitis is ubiquitous and has the potential to contribute significantly to the systemic inflammatory burden of an individual (Wahaidi et al. 2011; Leishman et al. 2013; Eberhard et al. 2013 ). The causative relationship between bacterial plaque (biofilm) and gingival inflammation was well demonstrated in studies using a model for the development of experimental gingivitis (Loe et al. 1965) . These studies also demonstrated that gingivitis is clinically reversible following removal of the etiologic biofilm (Loe et al. 1965; Versteeg et al. 2005; Salvi et al. 2009; Branco et al. 2015) . As gingivitis is rapidly inducible and reversible (Loe et al. 1965) , we suggest that this model is ideal for the assessment of local (i.e., oral cavity) and systemic (i.e., peripheral blood) changes in PMN activation during the development and resolution of gingivitis.
Gingivitis is an established risk factor for chronic periodontitis Albandar 2014; Kinane et al. 2017) . But the factors regulating the transition from gingivitis to periodontitis are not understood. In this regard, it is simply not possible, by using clinical measures of gingivitis, to determine a priori what patients with gingivitis will actually develop periodontitis if their gingivitis is left untreated. By investigating inflammation levels and corresponding changes in PMN subsets during the transition from gingival health to the earliest stage of periodontal disease (gingivitis), we might be able to determine a patient's susceptibility to oral inflammation and periodontal disease risk and understand more clearly how the innate immune system maintains oral health in the presence of the oral biofilm. This should ultimately lead to identification of novel biomarkers of early periodontal disease to facilitate early diagnosis prior to tissue damage occurring as a result of the development of chronic periodontitis. Therefore, the aim of the present study is to use the full-mouth experimental gingivitis model to determine oral tissue and blood PMN counts and PMN activation status as the periodontium transitions from health to gingivitis and back to health.
Materials and Methods

Study Population
The study was designed as a singlearm clinical trial. Participants were selected according to the following inclusion criteria: 1) 18 to 30 years old, 2) nonsmokers, and 3) no active or previous history of periodontal diseases, chronic aphthous ulcers, or tonsillitis. All subjects were verified to be periodontally healthy at the initiation of the study.
Exclusion criteria were as follows: 1) presence of systemic diseases (i.e., type I or type 2 diabetes, cardiovascular disease); 2) pregnancy or breastfeeding; 3) physical factors that could interfere with adequate oral hygiene procedures; 4) history of drug abuse; 5) allergic diathesis; 6) medications (in particular, current medication with nonsteroidal or steroidal anti-inflammatory drugs, analgesics, or antibiotics) within 9 wk before start of the study; 7) untreated carious lesions and 8) maxillary or mandibular orthodontic appliances, fixed or removable (permanent lingual retainers on maxillary and mandibular incisors were accepted); and 9) the presence of endosseous dental implants. Based on previous studies (Aboodi et al. 2011; Lakschevitz et al. 2013 ) looking at oral PMN subset changes during periodontal disease development and CD (cluster of differentiation) marker changes, the sample size calculation was done, and it revealed that the study group should be composed of 25 volunteers to perform the statistical correlation analysis (β = 80% and α = 5%).
Active recruitment took place at the University of Toronto downtown campus, inviting all volunteers to contact the trial committee by using flyers. Social network advertisements were also used for recruitment to increase the pool of potential participants exposed to the trial. Flyers and advertisements invited volunteers who were interested in participating in the trial to email their phone number to the study coordinator/principal investigator. The study coordinator then called the volunteer, and during this phone call, the participants were asked to answer a short recruiting questionnaire. Based on this questionnaire, participants were invited to a screening meeting. Participant recruitment was done in 3 stages. First recruitment was done from June 20, 2016, to July 22, 2016, and second recruitment was from November 3, 2016, to December 14, 2016. Final recruitment was done from March 15, 2017 , to April 11, 2017 . Males and females were recruited in equal proportion (1:1). Data collection commenced on July 6, 2016, and ended on June 27, 2017. Participants who met the preliminary inclusion criteria were scheduled for a dental screening appointment to confirm their eligibility. Subjects eligible to participate were given precise instructions about the experimental procedures and an explanatory pamphlet with details on the study design. All subjects signed an informed consent. Each subject was followed for a 35-d period with weekly follow-up visits. All study procedures were carried out at the Oral Reconstruction Clinic at the Faculty of Dentistry, University of Toronto as well as under the auspices of the Centre for Advanced Dental Research and Care, Mount Sinai Hospital/Sinai Health System. The study was approved by the University of Toronto Health Science Research Ethics Board (32899). This study conformed to STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines.
Study Design
Gingival inflammation was induced in subjects using the experimental gingivitis model developed by Loe et al. (1965) (Fig. 1) . This model was used as a model for inflammatory status in the oral cavity that may represent an inflammatory condition affecting the majority of cases in the general population (Versteeg et al. 2005; Salvi et al. 2009; Branco et al. 2015) . All participants received scaling and polishing of all tooth surfaces to remove all supra-and subgingival plaque, stain, and calculus. In addition, oral hygiene instructions were given 1 wk before initiating the cessation of oral hygiene for 3 wk. Subsequently, subjects were asked to abstain from all oral hygiene procedures for a period of 21 d, which was the exposure of this study. This induction period was followed by a resolution phase with resumption of oral hygiene for 14 d. At each visit, the oral hygiene status of the participants was evaluated and oral rinse samples were collected. Oral hygiene status was assessed by clinical examination of pocket depths, bleeding on probing (BOP), gingival index (GI), and plaque index (PI). PI and GI were assessed at 4 aspects of each tooth (mesial, buccal, distal, and lingual) using the criteria of the plaque index system (Loe and Silness 1964) and the gingival index system (Löe and Silness 1963). Blood was drawn into a vacutainer with sodium citrate as an anticoagulant. The questionnaire administration, oral examination, and oral and blood sample collection were done by the principal investigator. For details of the clinical assessment, see supplemental appendix.
Sample Collection and Processing
Blood and oral samples were obtained as previously described (Lakschevitz et al. 2013 ). Whole-blood and oral rinse samples were fixed immediately with 1.6% paraformaldehyde to preserve native surface expression of CD markers on PMNs (Fine et al. 2016 ). Erythrocytes were eliminated by isotonic lysis in blood. Epithelial cells and debris were removed by filtering through 40-µm and 11-µm nylon mesh filters. These processes have been demonstrated to produce PMN suspensions with a purity of >95% PMNs (Lakschevitz et al. 2013 ).
Multicolor Flow Cytometry
Whole-blood leukocytes and oral PMNs (5 × 10 5 ) were resuspended in 50 µL fluorescence-activated cell sorting (FACS) buffer and labeled with 8 CD marker panel of antibodies (Fine et al. 2016) . The markers were classified into 4 categories based on function: degranulation/activation markers (CD63, CD64, and CD66a), immunoregulation markers (CD16 and CD14), adhesion markers (CD11b and CD18), and complement regulators (CD55). Cells were labeled with antibodies for 30 min on ice and washed 3 times with FACS buffer. At least 2 × 10 4 gated events were acquired with an LSR Fortessa (BD Biosciences) flow cytometer. For each CD marker, appropriate fluorescently tagged isotype control antibodies were used to determine autofluorescent signals, which were subtracted from mean fluorescence intensities (MFIs). Flow cytometer channel voltages were calibrated manually with rainbow beads to normalize sample acquisition on different days to ensure comparability of data obtained from different FACS runs. As well, samples from 1 healthy volunteer were run on multiple occasions to confirm reproducibility on different days, while other samples were stained in duplicate on a given day to confirm that identical results could be expected. Compensation was performed with single-stained OneComp eBeads (eBioscience). Data were analyzed with FlowJo software (vX). Power analysis was performed to estimate the number of samples necessary.
Statistical Analysis
The statistical unit was the individual subject, and graphs were made for all clinical and laboratory recordings using means and their accompanying standard errors (±1 SE). Clinical parameter change (PI, GI, BOP, and mean pocket depth), oral and blood PMN change, and oral and blood CD marker change over time were considered outcome measures. Longitudinal changes that developed during induction, establishment, and regression of gingivitis for each subject were compared to that subject's baseline measure and allowed for the computation of fold-changes, which would eliminate problems associated with expected variances in baseline measures between participants. Repeated-measures analysis of variance (ANOVA), including pairwise comparison of time data with the Fisher least significance difference (LSD) test, were performed to identify the time trends of clinical parameters as well as the laboratory-based findings. Subsequently, the Mann-Whitney test was applied for group comparison. To compare oral PMN data with clinical parameters, Spearman rank correlation tests were performed. Statistical evaluation was computed using SPSS 24 (SPSS, Inc.). Tests were 2-tailed and interpreted at P ≤ 0.05.
Results
Characteristics of the Study Population
Fifty-three individuals were screened at the faculty of dentistry at the University of Toronto and Centre for Advanced Dental Research and Care, Mount Sinai Hospital from June 20, 2016, to March 15, 2017; of those, 30 met the inclusion criteria and were selected for the study. However, 5 subjects withdrew consent before starting the study proper (Appendix Table 1a ). A total of 25 participants completed the study. The first subject in was on July 6, 2016, and last subject out was on June 27, 2017. The mean age of participants was 22.4 ± 3.1 years (Appendix Table 1b ). All initial clinical parameters, as well as baseline oral PMN counts, were not significantly different when compared on the basis of sex (Appendix Table 2 ). Thus, data from both sexes were pooled for further analyses of time effects.
Clinical Parameters and Oral PMN Changes during Experimental Gingivitis
All clinical parameters of gingival disease increased progressively during the 21-d induction period (mean PI [P < 0.001], mean GI [P < 0.001], mean BOP [P < 0.001], and mean pocket depth (MPD) [P < 0.001]) and retuned to baseline levels during the resolution phase (21-35 d) ( Fig. 2A) . Oral PMN levels similarly increased progressively during the 21-d induction compared to baseline. However, unlike the clinical measures, PMN levels did not return to baseline levels during the resolution phase (Fig. 2B) . Changes in the microscopic morphological features of oral PMNs were observed on WrightGiemsa staining of the oral rinse samples (Appendix Fig. 1 ). In particular, nuclear decondensation occurred during the 21-d induction period but was not present during the resolution phase. As expected, extracellular debris increased during this period.
Differential CD Marker Expression of Oral PMNs during Experimental Gingivitis
The mean geometric MFI for each CD marker was assessed on oral PMNs for each subject and compared to their baseline to determine the fold-change. The levels of CD63 (P = 0.004), CD11b (P = 0.002), CD16 (P < 0.001), and CD14 (P < 0.001) on oral PMNs decreased during the induction phase and returned to normal during the resolution stage, whereas CD55, CD66a, CD64, and CD18 were not changed significantly during the trial (Fig. 3A, B ).
Blood PMN Changes during Experimental Gingivitis
There was a steep increase in blood PMN levels during the first 7 d of the induction period, which was maintained through day 21. During the resolution phase, mean levels of blood PMNs returned to baseline levels (Appendix Fig. 2) . We assessed the same CD markers on PMN in circulation during the trial. CD55 (P < 0.001), CD11b (P < 0.07), CD63 (P < 0.04), and CD66a (P < 0.06) increased significantly during the induction phase (Fig. 3C, D) , whereas CD14, CD18, CD16, and CD64 did not change significantly. We compared the oral and blood levels for each CD marker and confirmed as we have shown previously (Fine et al. 2016 ) that the geometric MFI (gMFI) on oral PMNs is always significantly higher than the gMFI on blood PMNs for CD63, CD11b, CD14, CD55, and CD66a (Appendix Fig. 3 ). This reflects the higher state of activation for oral PMNs under all health conditions compared to those in circulation.
Patient Subsets Based on Degree of Inflammation
We observed that the 25 subjects could be differentiated into 2 discrete groups based on their clinical parameters and their oral PMN levels at day 21. A subset of the research subjects displayed severe inflammation based on their clinical parameters and a more than 1.5-fold change in their oral PMN counts during the induction phase (Appendix Table   3a ). To differentiate these 2 populations objectively, we used median values of the distribution of GI, BOP and MPD, and oral PMN on day 21 as cutoff values (Appendix Table 3b ). Some of these cutoff values were also described in previous research studies (Loe and Silness 1963; Idrees et al. 2014 ). According to these research studies, the subject's gingival health, which Figure 2 . Clinical parameters change significantly during experimental gingivitis. (A) Histograms representing the trends of mean plaque index (PI), mean gingival index (GI), mean bleeding on probing (BOP), and mean pocket depth (MPD) (±1 SE) during experimental gingivitis for all subjects (n = 25). P values were determined by repeated-measures analysis of variance (ANOVA). d = P < 0.001; c = P < 0.01; b = P < 0.05. (B) Fold-change in oral PMN counts in experimental gingivitis. Mean fold-change of oral PMNs (±1 SE) during experimental gingivitis period is shown. P values were determined by repeated measures ANOVA. c = P < 0.01; b = P < 0.05. Figure 3 . PMN immunophenotype changes during experimental gingivitis. (A) Oral PMN activation during experimental gingivitis is determined by differential cluster of differentiation (CD) marker expression. Mean fold-change in 6 oral CD markers compared to baseline (±1 SE) are shown for all 25 subjects. P values were determined by repeated-measures analysis of variance (ANOVA). d = P < 0.001; c = P < 0.01; b = P < 0.05; a = P < 0.1. (B) Histograms of oral CD marker change during experimental gingivitis in 1 representative research subject. (a) represents the oral CD63 change during experimental gingivitis in research subject 18 (P18), which mimics the same pattern of oral CD63 change during the time course for all 25 subjects. (b), (c), (d), (e), and (f) represent the oral CD11b, CD16, CD14, CD55, and CD66a change, respectively, in research subject 21 (P21) during the experimental gingivitis, and the trends are similar to the time trends of those CD markers for all 25 subjects. (C) Blood PMN activation during experimental gingivitis is determined by differential CD marker expression. Line graphs depict mean fold-change of 6 blood CD markers (±1 SE) for all 25 subjects. P values were determined by repeated-measures ANOVA. c = P < 0.01; b = P < 0.05; a = P < 0.1. (D) Histograms of blood CD marker change during experimental gingivitis in 1 representative research subject. (a) represents the blood CD55 change during experimental gingivitis in research subject 22 (P22), which mimics the same pattern of blood CD55 change during the time course for all 25 subjects. (b), (d), and (e) represent the blood CD63, CD66a, and CD14 change, respectively, in research subject 16 (P16) during the experimental gingivitis, and the trends are similar to the time trends of those CD markers for all 25 subjects. (f) represents the blood CD16 change in research subject 21 (P21). gMFI, geometric mean fluorescence intensity.
was assessed using GI, was assigned as follows: no inflammation (<0.1), mild inflammation (0.1-1.0), moderate inflammation (1.1-1.9), and severe inflammation (2-3). The upper level of the range of moderate inflammation was 1.9. After statistical analysis, we found the median value of GI as 2, which is the upper level of moderate gingival inflammation of Loe and Silness (1963) and Idrees et al. (2014) . Therefore, we used the cutoff for GI as 2. In the literature, we did not find cutoff levels for BOP and MPD to classify different stages of gingival inflammation in experimental gingivitis. Therefore, we used the median values of BOP and MPD as cutoff levels to classify the subjects as the surrogate cutoffs for the severity of gingival inflammation.
Finally, case definitions were generated to classify subjects into a high level of inflammation (HLI) group and a low level of inflammation (LLI) group (Appendix Table 3c ). According to this classification, 8 subjects were in the HLI group and 17 subjects were in the LLI group (Appendix Table 4 ).
Overall, in both groups, there was an increase in all clinical parameters during the induction phase and a decrease during the resolution phase of experimental gingivitis (Fig. 4A-C) . The differences between the 2 groups, with respect to all clinical parameters, were significant at all time points except at day 35, when the difference between the 2 groups in relation to GI was not statistically significant (Appendix Table  5A -D). Further, increasing PI, GI, BOP, and MPD were highly correlated with the oral PMNs in the HLI group on day 21 (Appendix Table 6 ). However, there was no difference between HLI and LLI groups for oral CD markers as well as for blood PMNs.
Discussion
PMNs are key effector cells in the maintenance of periodontal health and the pathogenesis of periodontal diseases (Scott and Krauss 2012; Hajishengallis et al. 2015) . This study focuses on specific circulatory and oral PMN activation state changes during experimentally induced gingivitis in healthy adults. The periodontal diseases provide the ideal model to study PMNs due to the 1) ease of collection of these cells from the oral cavity during health and disease, 2) noninvasive rapid clinical access for disease severity assessment and monitoring, and 3) reversible inflammation induction using the classic experimental gingivitis model. We have shown previously that oral PMN activation states differ in oral health and chronic periodontitis, but how these PMN activation states transition during the shift from oral health to gingivitis had not yet been investigated.
To address this, we enrolled 25 healthy subjects between the ages of 18 and 30 years in which all 25 subjects completed the 35-d study. Participant compliance was verified by the increase in PI and GI over the induction phase, with a strong positive correlation between PI and GI (ρ > 0.5). Our clinical findings are consistent with previous experimental gingivitis studies that found significant gradual buildup in inflammation up to day 21 with reversal of gingival inflammation and reinstatement of oral hygiene procedures (Loe et al. 1965; Offenbacher et al. 2010; Trombelli et al. 2010; Wahaidi et al. 2011; Leishman et al. 2013) . As shown by our data, the participants displayed restoration of periodontal health according to clinical parameters, returning to baseline by day 35. Interestingly, oral PMN levels increased as expected during the induction phase, but for the study population used here, the levels were found to be only 2-fold higher versus baseline, by day 21. While Landzberg et al. (2015) showed that oral PMN levels are a good indicator of chronic periodontitis with oral PMN levels increasing by as much as 10-fold over baseline in disease, they found that oral PMN levels in clinical gingivitis increased by only 1.1-to 1.2-fold above baseline health levels. The change we observed here in oral PMN levels in patients with the LLI group was consistent with the Landzberg et al. data, suggesting that the majority of the population displays a minimal influx of PMN in gingivitis. However, as shown here in patients with a HLI, there was a much more robust influx of PMNs similar to what is observed in patients with periodontitis (Landzberg et al. 2015) . Given this finding, it is interesting to hypothesize that oral PMN influx could be used as a biomarker to identify subjects with an at-risk phenotype for gingivitis to periodontal disease transition. Indeed, the proportion of patients with higher PMN levels correlates with the fraction of subjects who have been shown to develop loss of attachment in the presence of gingival inflammation (Demmer et al. 2010; Li et al. 2010) .
Interestingly, we noted that oral PMN levels did not return to baseline by day 35, even though the tissues appeared clinically healthy. It is possible that inflammation induces transient changes in the capillary beds that take longer to return to normal, resulting in some persistent PMN influx despite the resolution of inflammation following elimination of the biofilm. Alternatively, if after longer-term studies are done, we identify a subpopulation of patients in whom PMN activation and/or levels are significantly delayed in their return to predisease levels, this could point toward the notion that the innate immune system and periodontal vascular system may be delayed in their return to the original healthy state following insult elimination. This delay could put some patients at risk for the development of periodontitis if they have experienced a long-enough exposure to gingivitis.
Oral PMN Activation State Is Reduced during Experimental Gingivitis
On average in our gingivitis cohort, we observed a reduction in PMN activation state based on expression of oral PMN CD markers during the gingivitis regime, which returned to baseline with resumption of oral hygiene. These results differ fundamentally from the oral PMN activation phenotype that we observed in periodontal disease (Fine et al. 2016) , which was characterized by upregulated expression of several PMN activation markers, including CD63 and CD11b, suggesting fundamental differences in PMN responses during early development of inflammation/ gingivitis compared to periodontal disease. This suggests that in early gingivitis, the PMNs are able to contain the bacteria due to their increasing numbers without resorting to their normal full complement of functions that can often be quite damaging to the periodontium. Oral PMNs carry out several antimicrobial functions, including phagocytosis, degranulation, generation of reactive oxygen species (ROS), and NETosis in response to oral pathogens (Landzberg et al. 2015) . The drop in expression of CD16, the lowaffinity Fc receptor, during experimental gingivitis, is consistent with elevated phagocytosis as a result of increased oral bacterial load (Lakschevitz et al. 2013) . The lower levels of the other CD markers suggest minimal degranulation/ activation suggestive of a more guarded and controlled PMN response due to a sufficient number of PMNs in relation to bacterial load. This would support the notion that phagocytosis is the primary response and degranulation would occur as a secondary response as the inflammatory process progresses.
Circulating PMN Activation Occurs during Experimental Gingivitis
The existing literature provides strong evidence for an association between periodontitis and systemic inflammation (Beck and Offenbacher 2002; Nibali et al. 2007 ; El-Shinnawi and Soory 2013), but relatively little is known regarding the direct and indirect systemic effects of gingivitis on systemic inflammation (Wahaidi et al. 2011; Leishman et al. 2013) . Numerous studies have reported the impact of severe periodontal disease on circulating PMN levels (Loos 2005) . Through a case control study, Monteiro et al. (2009) found significantly higher peripheral PMN counts in a group of adults with periodontitis compared to a group of healthy participants. In our gingivitis cohort, we observed an increase in total circulating PMNs at the second and third weeks after cessation of oral hygiene, relative to day 0. After resumption of hygiene, blood PMN levels returned to baseline levels. In addition to blood PMN counts, we also observed increased expression of CD markers of activation on blood PMNs, including CD55, CD11b, CD63, and CD66a. These changes occurred within the first week of the gingivitis regimen, indicating that systemic activation of PMNs by the oral inflammation occurs quite soon after cessation of oral hygiene and early development of gingival inflammation. CD marker upregulation on PMN plasma membranes continued up to day 21 and returned to normal after resumption of oral hygiene, indicating a direct link between oral health status and systemic activation of PMN in the blood. This is further evidence that oral inflammation leads to an activation of circulating neutrophils, supporting the hypothesis that oral inflammation can lead to direct activation of immune cells in circulation with the possibility of a hyperinflammatory response secondary to periodontal diseases. Our findings are similar to those shown by others (Wahaidi et al. 2011) , where hyperactivity of circulatory PMNs and a significant increase in levels of systemic endotoxins were found following 21 d of dental plaque accumulation. Given these findings, it was suggested that the observed increase in PMN activity might be linked to increases in circulating bacteria/endotoxin or the presence of a local oral infection during the experimental gingivitis model. It has also been shown that in experimentally induced gingivitis, the presence of a low-level oral bacterial infection led to acute systemic inflammation with enhanced systemic levels of C-reactive protein, interleukin 6, and monocyte chemoattractant protein 1 (MCP-1) and monocyte activation in young healthy adult participants (Eberhard et al. 2013) . Thus, the accumulation of high levels of systemic endotoxins in circulation as a result of gingivitis could explain the increase in circulating activated PMNs measured in our participants. The increase in CD11b could also explain the increased influx of PMNs into the periodontium as this receptor is known to be involved in PMN exit from circulation. With the focus on identifying the possible impact of oral disease on systemic health issues, these data suggest that PMN activation states in circulation could be a valid biomarker for monitoring systemic changes associated with oral health that could link to immune-mediated diseases/ conditions, including preterm births and cardiovascular disease.
Two Distinct Patient Inflammation Phenotypes in Experimental Gingivitis
Here, we identified 2 subsets of individuals with experimental gingivitis based on clinical parameters and oral PMN counts. In the LLI group, oral PMN counts remained relatively consistent over time, whereas oral PMN counts in the HLI group increased significantly up to day 21 and dropped afterward. This suggests that the oral inflammatory load of HLI was more sensitive to plaque accumulation over time compared to LLI. This influx of oral PMN in the HLI group was coincident with high levels of clinical inflammation. This hyperinflammatory gingivitis phenotype may suggest that this subset of patients may be more susceptible to transitioning to periodontitis if proper oral hygiene practices are not maintained. Studies have suggested that about one-fourth to one-third of the population is thought to have a genetic susceptibility to periodontal disease (Ericsson et al. 2009; Demmer et al. 2010; Li et al. 2010) , which is consistent with the ratio of HLI/ LLI in our population. Future studies will focus on this hypothesis by identifying the immune biomarkers that differentiate the HLI from the LLI group and determining if these biomarkers are also more common in patients with distinct forms of periodontitis.
Author Contributions
N.C. Wellappuli, contributed to data acquisition, analysis, and interpretation, drafted and critically revised the manuscript; N. Fine, contributed to data acquisition, analysis, and interpretation, critically revised the manuscript; H.P. Lawrence, contributed to data analysis and interpretation, critically revised the manuscript; M. Goldberg, contributed to data acquisition, critically revised the manuscript; H.C. Tenenbaum, contributed to data interpretation, critically revised the manuscript; M. Glogauer, contributed to conception, design, data analysis, and interpretation, drafted and critically revised the manuscript. All authors gave final approval and agree to be accountable for all aspects of the work.
